An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Perimeter Medical Imaging AI to Participate in the LD Micro Main Event Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) will participate in the LD Micro Main Event Investor Conference from October 12-14, 2021, in Los Angeles, CA. CEO Jeremy Sobotta will present on October 12 at 3:30 pm PT. Perimeter's S-Series Optical Coherence Tomography (OCT) is FDA-cleared and offers real-time tissue visualization, potentially improving patient outcomes. The company is also developing the B-Series OCT with ImgAssist AI, funded by a $7.4 million grant from CPRIT, aimed at reducing re-operation rates in breast cancer surgeries.
Positive
None.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that Perimeter will participate in the LD Micro Main Event Investor Conference taking place October 12-14, 2021 in Los Angeles, CA:
Jeremy Sobotta, Perimeter’s Chief Executive Officer, will be host a company presentation at 3:30 pm PT (6:30 pm ET) on Tuesday, October 12, 2021 and will be available for one-on-one meetings. The live webcast of the company presentation can be accessed by registering on the conference website.
Details on company presentations and webcasts can be found on the “Investors” section of Perimeter’s website at https://ir.perimetermed.com/. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Perimeter S-Series OCT
Cleared by the U.S. FDA, Perimeter S-Series Optical Coherence Tomography (OCT) is a novel medical imaging system that provides clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. Giving physicians the ability to visualize microscopic tissue structures “real time” in the operating room has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system.
About Perimeter B-Series OCT with ImgAssist AI
Perimeter is advancing the development of its proprietary, next-gen “ImgAssist” artificial intelligence technology under its ATLAS AI project, which is made possible, in part, by a US$7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery.
About Perimeter Medical Imaging AI, Inc.
With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company’s dedication to helping surgeons, radiologists, and pathologists use Perimeter’s imaging technology and AI in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
What is the purpose of the ImgAssist AI technology developed by Perimeter?
The ImgAssist AI technology aims to enhance breast conservation surgery outcomes by reducing re-operation rates.
What financial support has Perimeter Medical Imaging AI received for its ImgAssist AI project?
Perimeter Medical Imaging AI received a $7.4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) for the ImgAssist AI project.
